Clinical Trial Update: A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A pilot Phase 1/2 trial evaluating BR55 ultrasound contrast agent for assessing prostate cancer has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BR55

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-08-27